Neuraxis, Inc. (NRXS) - Total Liabilities
Based on the latest financial reports, Neuraxis, Inc. (NRXS) has total liabilities worth $3.00 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See working capital position of Neuraxis, Inc. to evaluate short-term liquidity relative to the company's equity base.
Neuraxis, Inc. - Total Liabilities Trend (2020–2025)
This chart illustrates how Neuraxis, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see NRXS total asset value.
Neuraxis, Inc. Competitors by Total Liabilities
The table below lists competitors of Neuraxis, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shemen Industries Ltd
TA:SMNIN
|
Israel | ILA88.93 Million |
|
Western Energy Services Corp.
TO:WRG
|
Canada | CA$106.06 Million |
|
Jinro Distillers Co. Ltd
KQ:018120
|
Korea | ₩14.06 Billion |
|
Rand Mining Ltd
AU:RND
|
Australia | AU$6.63 Million |
|
Tah Kong Chemical Industrial
TWO:4706
|
Taiwan | NT$132.58 Million |
|
Tongyang
KO:001520
|
Korea | ₩689.99 Billion |
|
Choppies Enterprises Ltd
JSE:CHP
|
South Africa | ZAC2.70 Billion |
|
Kyungin Synthe
KO:012610
|
Korea | ₩290.57 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Neuraxis, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Neuraxis, Inc. balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neuraxis, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neuraxis, Inc. (2020–2025)
The table below shows the annual total liabilities of Neuraxis, Inc. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.00 Million | +11.70% |
| 2024-12-31 | $2.69 Million | +40.63% |
| 2023-12-31 | $1.91 Million | -72.89% |
| 2022-12-31 | $7.05 Million | +344.74% |
| 2021-12-31 | $1.59 Million | +38.43% |
| 2020-12-31 | $1.15 Million | -- |
About Neuraxis, Inc.
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional … Read more